Categories: News

Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).

Entrada/Investor Contact
Karla MacDonald
VP, Corporate Communications
kmacdonald@entradatx.com

Media Contact
Aulani Capuchin
Real Chemistry
acapuchin@realchemistry.com
(559) 355-2673

Staff

Recent Posts

ZetrOZ System’s sam(R) Ultrasound Treatment Helps Top Triathlete Return to the Boston Marathon

Former triathlon champ Claudia McCoy used the breakthrough wearable ultrasound unit to boost her recovery…

2 hours ago

Coro Medical Prepares to Roll Out Project AED365 Nationwide Donation Initiative

Project AED365 Aims to Empower Communities, Youth Organizations, First Responders, and more by Providing Lifesaving Automated…

5 hours ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages…

5 hours ago

Blazesoft Spreads Holiday Cheer with $250,000 Donation to Mackenzie Health Foundation

This heartfelt donation demonstrates Blazesoft's commitment to corporate social responsibility with a generous gift to…

5 hours ago

Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

GOLETA, Calif.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products…

8 hours ago

Bemax Inc. Announces Second Quarter Financial Results

- Revenue grew to $1,078,090, an increase of over $1million year-over-yearDallas, Georgia--(Newsfile Corp. - December…

8 hours ago